

1 **Plasma Proteomic Signatures of Physical Activity Provide Insights into Biological Impacts**  
2 **of Physical Activity and its Protective Role Against Dementia.**

3  
4 **Author List**

5 Gayatri Arani<sup>1\*</sup>, Amit Arora<sup>1,2</sup>, Shuai Yang<sup>1</sup>, Jingyue Wu<sup>1</sup>, Jennifer N. Kraszewski<sup>1</sup>, Amy  
6 Martins<sup>1</sup>, Alexandra Miller<sup>1,3</sup>, Zebunnesa Rahman<sup>4</sup>, Ayan Jafri<sup>1</sup>, Chengcheng Hu<sup>1</sup>, Leslie V.  
7 Farland<sup>1</sup>, Jennifer W. Bea<sup>5,6</sup>, Dawn K. Coletta<sup>7,8,9,10</sup>, Daniel H. Aslan<sup>11</sup>, M Katherine Sayre<sup>12,13</sup>,  
8 Pradyumna K Bharadwaj<sup>11</sup>, Madeline Ally<sup>11</sup>, Silvio Maltagliati<sup>12,14</sup>, Mark H C Lai<sup>12,15</sup>, Rand  
9 Wilcox<sup>15</sup>, Eco de Geus<sup>16,17</sup>, Gene E. Alexander<sup>11,18,19,20,21,22</sup>, David A. Raichlen<sup>12,15,23</sup>, Yann C.  
10 Klimentidis<sup>1,18,24</sup>

- 11  
12 1. Department of Epidemiology and Biostatistics, College of Public Health, University of Arizona,  
13 Tucson, AZ, USA.  
14 2. Department of Biomedical Informatics, College of Health Solutions, Arizona State University,  
15 Tempe, AZ, USA.  
16 3. College of Medicine, University of Arizona, Tucson, AZ, USA.  
17 4. Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health,  
18 University of Memphis, Memphis, TN, USA.  
19 5. Department of Health Promotion Sciences, University of Arizona, Tucson, AZ, USA  
20 6. University of Arizona Cancer Center, Tucson, AZ, USA  
21 7. Department of Physiology, University of Arizona, Tucson, AZ, USA  
22 8. Department of Medicine, Division of Endocrinology, University of Arizona, Tucson, AZ, USA.  
23 9. Department of Clinical and Translational Genomics, University of Arizona, Tucson, AZ, USA  
24 10. Center for Disparities in Diabetes, Obesity and Metabolism, University of Arizona, Tucson, AZ,  
25 USA.  
26 11. Department of Psychology, University of Arizona, Tucson, AZ, USA  
27 12. Department of Anthropology, University of Southern California, Los Angeles, CA, USA.  
28 13. Department of Anthropology, University of California Santa Barbara, Santa Barbara, CA, USA.  
29 14. University of Grenoble Alpes, SENS, Grenoble 38000, France.  
30 15. Department of Psychology, University of Southern California, Los Angeles, CA, United States  
31 16. Department of Biological Psychology, Vrije Universiteit, Amsterdam, the Netherlands.  
32 17. Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, the Netherlands.  
33 18. BIO5 Institute, University of Arizona, Tucson, AZ, USA  
34 19. Evelyn F. McKnight Brain Institute, University of Arizona, Tucson, AZ, USA.  
35 20. Department of Psychiatry, University of Arizona, Tucson, AZ, USA.  
36 21. Neuroscience Graduate Interdisciplinary Program, University of Arizona, Tucson, USA.  
37 22. Arizona Alzheimer's Consortium, Phoenix, AZ, USA.  
38 23. Human and Evolutionary Biology Section, Department of Biological Sciences, University of  
39 Southern California, Los Angeles, CA, USA.  
40 24. Genetics Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA

41 **\*Corresponding author:** [aranin@arizona.edu](mailto:aranin@arizona.edu)

42

43 **ABSTRACT**

44  
45 Physical activity (PA), including sedentary behavior, is associated with many diseases, including  
46 Alzheimer’s disease and all-cause dementia. However, the specific biological mechanisms  
47 through which PA protects against disease are not entirely understood. To address this  
48 knowledge gap, we first assessed the conventional observational associations of three self-  
49 reported and three device-based PA measures with circulating levels of 2,911 plasma proteins  
50 measured in the UK Biobank ( $n_{\max}=39,160$ ) and assessed functional enrichment of identified  
51 proteins. We then used bi-directional Mendelian randomization (MR) to evaluate further the  
52 evidence for causal relationships of PA with protein levels. Finally, we performed mediation  
53 analyses to identify proteins that may mediate the relationship of PA with incident all-cause  
54 dementia. Our findings revealed 41 proteins consistently associated with all PA measures and  
55 1,027 proteins associated with at least one PA measure. Both conventional observational and MR  
56 study designs converged on proteins that appear to increase as a result of PA, including integrin  
57 proteins such as ITGAV and ITGAM, as well as MXRA8, CLEC4A, CLEC4M, GFRA1,  
58 ADGRG2, and PTGDS; and on proteins that appear to decrease as a result of PA such as LEP,  
59 LPL, INHBC, CLMP, PTGDS, ADM, OGN, and PI3. Functional enrichment analyses revealed  
60 several relevant processes, including cell-matrix adhesion, integrin-mediated signaling, and  
61 collagen binding. Finally, several proteins, including GDF15, ITGAV, HPGDS, BCAN, and  
62 MENT, were found to mediate the relationship of PA with all-cause dementia, implicating  
63 processes such as synaptic plasticity, neurogenesis and inflammation as mechanisms through  
64 which PA protects against dementia. Our results provide insights into how PA may affect  
65 biological processes and protect from all-cause dementia, and provide avenues for future  
66 research into the health-promoting effects of PA.

67  
68

## 69 INTRODUCTION

70  
71 Physical activity (PA) and sedentary behavior (SB), hereafter collectively referred to as PA, are  
72 associated with health benefits such as improving cardiovascular function, weight management,  
73 cognitive function, and mental health.<sup>1</sup> There are well-established associations between PA and  
74 decreased risk of several chronic diseases such as heart disease, type-2 diabetes, depression,  
75 anxiety, osteoporosis, and cancer.<sup>2,3</sup> PA is also increasingly recognized for its potential role in  
76 reducing the risk and progression of dementia.<sup>4-8</sup>

77  
78 Regular PA may enhance neuroplasticity and cognitive functioning through improved cerebral  
79 blood circulation, stimulation of neural tissue development, and the release of other  
80 immunological and endocrine factors.<sup>9-11</sup> Additionally, PA improves metabolic functioning, in  
81 part, by reducing systemic inflammation and oxidative stress, which are pathological  
82 mechanisms also implicated in all-cause dementia.<sup>12-15</sup> Although the neurocognitive benefits of  
83 PA are often observed, the precise mechanisms and biological underpinnings of this protection  
84 are not well understood.<sup>12,16</sup> Investigating the biological pathways that underlie the association  
85 between PA and all-cause dementia can increase opportunities for the precise and effective  
86 prevention and management of dementia.<sup>12</sup>

87  
88 Investigating circulating plasma protein levels offers a promising avenue to uncover the  
89 biological mechanisms underlying the health-promoting effects of PA.<sup>16,17</sup> These insights could  
90 pave the way for innovative applications in clinical practice, enabling more targeted and  
91 effective interventions.<sup>16,17</sup> However, previous human studies examining the relationship  
92 between PA and plasma protein levels have been based on relatively small sample sizes or small  
93 sets of measured proteins.<sup>18-22</sup> For example, Stattin et al., 2019 examined 184 proteins among  
94 6,500 individuals.<sup>18</sup> Moreover, only self-reported PA measures are typically examined.<sup>18,19</sup> While  
95 substantial progress has been made in understanding the proteomic changes associated with  
96 cardiovascular health and PA, there remains a critical gap in linking these molecular changes to  
97 cognitive outcomes such as dementia.<sup>17-24</sup> For instance, a study by Robbins et al., 2023  
98 demonstrated how plasma proteomic changes in response to exercise training are associated with  
99 cardiorespiratory fitness (CRF) adaptations, highlighting the diverse physiological pathways  
100 through which PA can confer cardiorespiratory benefits.<sup>25</sup> Furthermore, while previous research  
101 has attempted to find associations between PA and plasma protein levels, conventional  
102 observational studies may be biased by unmeasured and residual confounding factors, and  
103 reverse causation.<sup>26</sup> As a result, alternative study designs such as Mendelian randomization (MR)  
104 can help to assess causal relationships.<sup>26-28</sup>

105  
106 We performed the most extensive study to date testing the associations of PA with the levels of  
107 2,911 plasma proteins, using self-reported and device-based measures ( $n_{\max} = 39,160$ ) from the  
108 UK Biobank. We compared the evidence for causality across the different types of PA measures

109 and two study designs: a conventional observational study and a bi-directional MR study. We  
110 then assessed the functional enrichment of identified proteins and assessed whether any specific  
111 proteins mediate the relationship between PA and all-cause dementia in the UK Biobank (Figure  
112 1).

113  
114

## 115 **METHODS**

116

### 117 *UK Biobank proteomics*

118 The UK Biobank is a large prospective study with over ~ 500,000 participants aged 39-73 years  
119 at the time of recruitment between 2006 and 2010 [Sudlow, 2015].<sup>29</sup> Between November 2020  
120 and March 2021, the Pharma Proteomics Project (PPP) consortium selected 54,219  
121 representative participants through age, sex, and study center stratification for the proteomics  
122 sub-study (Sun et al. 2023, Nature).<sup>30</sup> Blood samples were obtained at each participant's baseline  
123 visit. The time of day of blood sample collection varied for each individual.<sup>30</sup>

124

125 Between May 2021 - November 2022, plasma profiling was performed using Olink Explore  
126 3072 (Uppsala, Sweden) technology, in which a matched pair of antibodies labeled with unique  
127 complementary oligonucleotides (proximity probes) bind to the respective target proteins in each  
128 sample.<sup>30</sup> The oligonucleotides come into proximity and hybridize with each other to enable  
129 DNA amplification of the protein signal, which is quantified on a next-generation sequencing  
130 read-out, as detailed elsewhere.<sup>30</sup> Antibodies for 2,923 unique plasma proteins were available in  
131 the UK Biobank PPP.<sup>30</sup> The protein panel covers major biological pathways in inflammation,  
132 oncology, cardiometabolic, and neurological domains.<sup>30</sup> The performance of each protein assay  
133 is validated for specificity, sensitivity, dynamic range, precision, scalability, detectability, and  
134 endogenous interference.<sup>30</sup> Additional details on sample batching, data pre-processing, and  
135 quality checking were previously published.<sup>29</sup> Quality control of the proteomic data for the  
136 current study was performed in R (version 4.33)<sup>31</sup> by excluding proteins with more than 20%  
137 missing values (n=12) and samples with more than 50% missing values, leaving a set of 2,911  
138 proteins for analyses.

139

### 140 *Conventional observational associations of physical activity and sedentary behaviors with 141 protein levels*

142 We used linear regression to examine the cross-sectional associations of six PA-related variables  
143 with each plasma protein. Three PA variables were self-reported: Moderate-to-Vigorous Physical  
144 Activity (MVPA), Vigorous Physical Activity (VPA), and Strenuous Sports and Other Exercises  
145 (SSOE). As previously described, these were derived from questionnaire responses obtained  
146 during the UK Biobank baseline assessment (2006-2010) (Klimentidis et al., 2018).<sup>32</sup>  
147 Additionally, three device-based PA measures were assessed in 2014 for associations with  
148 plasma protein levels measured 4-8 years earlier at the baseline visit.<sup>32</sup> A subset of 103,684  
149 participants agreed to wear a 3-axis logging accelerometer (AX3; Activity) for 24 hours per day

150 for seven days on their dominant wrist, from 2013 – 2015. These device-based measures were:  
151 average acceleration (AvgAcc), the fraction of accelerations >425 milligravities (FracAcc>425),  
152 and sedentary behavior (AccSed) derived from a machine-learning model<sup>33</sup> as applied in  
153 Raichlen et al., 2023.<sup>7</sup> The questions for self-reported PA measurements, participant device-wear  
154 information, and variable construction were created and transformed as previously described  
155 (Klimentidis et al., 2018). We applied consistent exclusion criteria and data quality control  
156 measures to the accelerometry-based measures. Individuals with at least 3 days of data were  
157 included in the study.<sup>7,32</sup>

158  
159 The numbers of participants with proteomic data and self-reported PA measures were as follows:  
160 MVPA: n=40,787, VPA n=10,502 physically active and 18,092 controls, SSOE: n=13,179  
161 physically active and 25,770 controls) and device-based measures (AvgAcc: n=9,851,  
162 FracAcc>425: n= 9,792, AccSed: n=9,806). We conducted linear regression for the independent  
163 relationship between each PA variable as the exposure and each protein as the outcome, resulting  
164 in a total of  $6 \times 2,911$  regressions. All proteins, along with MVPA and AvgAcc, were inverse  
165 normalized before analysis to ensure normality and comparability across variables. Each model  
166 assessing the PA-protein association was adjusted for age (at baseline or device use), sex, season  
167 (questionnaire or device use), race and ethnicity, body fat percentage (measured by Tanita  
168 BC418MA), alcohol intake (drinks per week), smoking status (never, former, current), education  
169 (college or higher vs. less), and the presence of major health conditions (cancer, type-2 diabetes,  
170 hypertension). All statistical analyses of conventional observational associations were performed  
171 using R software (version 4.3.3). We selected all PA-protein pairs with a  $p < 1.7 \times 10^{-5}$  as  
172 statistically significant, based on a Bonferroni correction for 2,911 tests. Although 6 PA  
173 measures were tested, this is a conservative correction given the substantial correlations among  
174 proteins and among PA measures.

175  
176 *Pathway and functional enrichment analyses*

177 We conducted gene enrichment analyses for the gene set corresponding to the proteins  
178 significantly associated with each PA measure and the set of proteins significantly associated  
179 with all six PA measures. We analyzed DAVID gene enrichment and functional annotation using  
180 the complete set of 2,911 Olink 3072 proteins as the background.<sup>34-35,36</sup> We derived enrichment  
181 terms for Gene Ontology (GO) biological process, and GO molecular function. A Benjamini-  
182 Hochberg correction was used to assess whether our identified genes are significantly enriched  
183 for specific functional pathways.

184  
185 *Bi-directional Mendelian randomization*

186 We performed bi-directional MR for PA and protein levels for all pairs with a significant  
187 conventional observational association. We assessed PA exposure SNPs selected at the  $p < 5 \times$   
188  $10^{-8}$  and  $p < 5 \times 10^{-6}$  thresholds. The stricter threshold ( $p < 5 \times 10^{-8}$ ) ensured the inclusion of  
189 high-confidence genetic variants, while the slightly relaxed threshold ( $p < 5 \times 10^{-6}$ ) allowed for

190 additional variants since some PA exposures had fewer than 5 SNPs at the  $p < 5 \times 10^{-8}$  threshold.  
191 We used GWAS of the same set of PA variables described above<sup>32</sup>, plus two additional self-  
192 reported measures based on larger sample sizes, by Wang et al. 2022<sup>37</sup>: leisure screen time (n=  
193 526,725) and MVPA during leisure time (n= 608,595). We used publicly available GWAS  
194 summary statistics reported in Sun et al. 2022<sup>38</sup> to genetically-instrument protein levels.  
195 Specifically, we used the GWAS based on the European ancestry subset in the UK Biobank PPP  
196 (n= 34,557) since this corresponds to the ancestry used in the PA GWAS. Additionally, we  
197 performed MR with each protein as the exposure, limiting our exposure SNPs to cis-pQTLs  
198 within one Mb up and downstream of the transcription start site for the respective protein-coding  
199 gene to reduce the potential for pleiotropic variants outside the protein-encoding gene.<sup>39</sup> All MR  
200 statistical analyses were performed in R (version 4.2) using the ‘TwoSampleMR’ package.<sup>40</sup>  
201 Clumping for MR was performed with Plink 1.9 using the ‘EUR’ subpopulation from 1,000  
202 Genomes as a reference. We first assessed results from the inverse variance weighted (IVW)  
203 method. When only one SNP exposure instrument was available, we applied the Wald ratio  
204 method and reported those results. To strengthen our findings, we examined the results of  
205 sensitivity analyses, including MR-Egger regression to account for directional pleiotropy, the  
206 weighted median method to account for the presence of invalid SNPs, and a mode-based  
207 estimator that grouped similar SNPs to minimize the impact of outliers. F-statistics for PA  
208 exposure instruments are presented elsewhere and are  $>10$ .<sup>41,42</sup> We selected all PA-protein pairs  
209 that showed evidence from MR for a causal effect in either direction, using a pre-set significance  
210 criterion of  $p < 4.9 \times 10^{-5}$ . This criterion was chosen based on a Bonferroni correction for the  
211 number of proteins tested. The significant protein-PA pairs were forwarded to the colocalization  
212 analysis.

### 213 214 *Colocalization*

215 We performed colocalization analyses for PA-protein pairs that showed significant associations  
216 in MR analyses to rule out the potential of pleiotropy that could bias the MR results. We used the  
217 ‘*coloc*’ package in R.<sup>43</sup> We applied the ‘*coloc.abf*’ function using a genomic region of +/- 250kb  
218 around the variants to assess the colocalization of PA measures and proteins.<sup>44</sup> We used the  
219 default threshold for colocalization evidence using the posterior probability (PP) of hypothesis 4  
220 ( $H_4$ : PA and protein have one shared common associated/causal variant for both measures). A PP  
221 of  $H_4 > 0.8$  was considered as nominal evidence of colocalization.

### 222 223 *Mediation and interaction analyses (4-way decomposition)*

224 Plasma proteins significantly associated with at least one PA measure (n=1,027) were analyzed  
225 using a four-way decomposition method to estimate the extent to which specific protein(s)  
226 mediate the PA-dementia relationship. Only participants aged 55 or older without a prior  
227 dementia diagnosis at the baseline visit were included in these analyses. Two primary models  
228 were utilized in the four-way decomposition analysis. For the exposure-mediator relationship, a  
229 linear regression model was used to estimate the association between PA (independent variable)

230 and each selected protein mediator (dependent variable). This model was adjusted for the  
231 following covariates: age, sex, season, race and ethnicity, education, alcohol consumption,  
232 smoking status, presence of chronic diseases, and body fat percentage. A Cox proportional  
233 hazards regression model was employed to examine the association between each protein  
234 mediator and the incidence of all-cause dementia. Follow-up time and dementia incidence data  
235 were extracted from the UK Biobank. All-cause dementia was identified through diagnoses  
236 recorded in inpatient hospital records and death registry data, as previously detailed.<sup>7</sup> Our  
237 definition encompassed all forms of dementia, including Alzheimer’s disease, vascular dementia,  
238 and other types. The follow-up period for dementia incidence began at the baseline assessment of  
239 self-reported PA (2006-2010) or at the time of device wear (2013-2015), depending on the  
240 specific analysis. Follow-up continued until the earliest occurrence of a dementia diagnosis, the  
241 last available health record, or the end of the study period in 2021. The four-way approach  
242 decomposes the total effect between PA and dementia into four main parameters: (1) Controlled  
243 Direct Effect (CDE): This parameter estimates the direct effect of a PA measure on the incidence  
244 of dementia, independent of the protein mediator.<sup>45</sup> The protein is set to a fixed value for the  
245 entire study population to mimic the absence of the mediator. In this study, the fixed value of  
246 each protein was set to the mean of that protein. (2) Reference Interaction (Intref): This  
247 parameter indicates the effect of PA on the incidence of dementia due to only an interactive  
248 effect between the PA and the protein on dementia. (3) Mediation interaction (Intmed): This  
249 parameter refers to the effect of a PA measure on the incidence of dementia from both mediation  
250 by the protein and the interaction between PA and the protein. (4) Pure Indirect Effect (PIE):  
251 Also referred to as “mediated main effect,” this parameter estimates how much of the  
252 relationship between PA and dementia is explained by the influence of a given protein, which in  
253 turn influences dementia.<sup>45</sup> Proteins with mediation (PIE)  $p < 4.9 \times 10^{-5}$  were considered  
254 proteome-wide statistically significant. We also report the proportion of the total effect that  
255 consists of pure indirect effect. We used the *med4way* command in Stata 17 (StataCorp, College  
256 Station, TX) to perform the four-way decomposition analysis.<sup>46</sup>

257

258

## 259 RESULTS

260

261 Our comprehensive findings are available through an interactive web platform (  
262 <https://github.com/klimentidis-lab/ProteomicsofPhysicalActivity2024.git>), where it is also  
263 possible to visually browse the complete set of results with interactive volcano plots.

264

### 265 *Conventional observational associations of physical activity with proteins*

266 Participants were 54% female and had a mean age of 56.8 (Supplementary Table S1). Across all  
267 three self-reported ( $n_{\max}=39,160$ ) and three device-based ( $n_{\max}=9,496$ ) PA measures  
268 (Supplementary Table S2), there were a total of 1,027 proteins (Supplementary Tables S3) that  
269 were significantly associated with at least one measure and 41 proteins (Supplementary Tables

270 S4) that were significantly associated with all six measures (Supplementary Tables S5-S10).  
271 Some of the strongest and most consistently associated proteins across self-report and device  
272 measures included increased levels of ITGAV, ITGAM, ITGA11, MXRA8, CA14, CLEC4A,  
273 MEGF10, MYOM3, MYL3, ADGRG2, ADAMTS8, and PON3, and decreased levels of LEP,  
274 GDF15, and IL6, among others (Figure 2).

#### 275 276 *Pathway enrichment*

277 The set of genes coding for the 41 proteins we found to be associated with every PA measure  
278 was enriched for several biological processes and molecular functions, including integrin-  
279 mediated signaling, cell-matrix adhesion, and collagen binding (Table 1). Carbohydrate binding  
280 and serine-type endopeptidase activity were significantly enriched in protein-coding genes  
281 specific to MVPA and VPA and to the set of 1,027 proteins associated with at least one PA  
282 measure (Supplementary Tables S11 & S12). Cell adhesion processes emerged as most  
283 prominently enriched for VPA, SSOE, and all device-based measures (Supplementary Table  
284 S11). The pathway enrichment analysis also revealed that cell adhesion mediated by integrins  
285 was consistently observed across four measures, including self-reported and device-based  
286 measures (Supplementary Table S11). Furthermore, proteins identified for AvgAcc and AccSed  
287 were found to participate in integrin-mediated signaling pathways (Supplementary Table S11).  
288 Integrin binding was recognized as a common pathway across the various device-based measures  
289 examined (Supplementary Table S11).

#### 290 291 *Mendelian randomization*

292 Of 1,027 proteins tested based on showing at least one significant ( $p < 1.7 \times 10^{-5}$ ) association in  
293 the above conventional observational analyses, we found 194 significant ( $p < 4.9 \times 10^{-5}$ ) MR  
294 IVW associations between PA exposure and protein level (with PA exposure SNPs at  $p < 5 \times 10^{-8}$ )  
295 and 280 proteins (IL6, LEP, ITGAV, MXRA8 and TNF were significantly associated with  
296 four or more measures) with the PA exposure SNPs at the  $p < 5 \times 10^{-6}$  threshold (Figure 3).  
297 Three proteins (DUSP13, FGR, and RAB6A) and one protein (FGR) were significant in the  
298 reverse direction at the  $p < 5 \times 10^{-8}$  and  $p < 5 \times 10^{-6}$  thresholds for selecting the protein exposure  
299 SNPs, respectively. Using only cis-pQTL SNPs as protein exposure instruments revealed four  
300 (SLC9A3R2, DUSP13, GOLM2, CCL11) and three (SLC9A3R2, AP3B1, CCL11) proteins at  
301 the  $p < 5 \times 10^{-8}$  and  $p < 5 \times 10^{-6}$  thresholds, respectively. MR sensitivity analyses generally  
302 revealed directionally consistent estimates for most IVW top hits (Supplementary Tables S13 to  
303 S22). Based on our colocalization analyses, 110 distinct proteins and PA-related SNP pairs were  
304 observed to have a posterior probability of  $> 0.80$  for a potential pleiotropic relationship (see  
305 Supplementary Table S23).

306  
307 To assess the consistency of the effect estimates of PA on protein levels across conventional  
308 observational and MR analyses, we plotted the beta coefficient estimates from the conventional  
309 observational analyses against the beta coefficient estimates from the MR analyses for each of  
310 the 1,027 proteins (Figure 4). When evaluating our results across the two study designs, we



311 emphasized proteins exhibiting directionally consistent effects and with univariable  $p < 1 \times 10^{-3}$ .  
312 We used a more liberal threshold for statistical significance, considering the lower null  
313 likelihood of directionally consistent results in both designs. We identified ITGAV, MXRA8,  
314 and LEP as exhibiting consistent associations across study designs and PA measures.

315

#### 316 *Mediation and interaction analyses*

317 There were up to 859 incident dementia cases identified among participants with both proteomic  
318 and PA data (Supplementary Table S24). Our investigation employing the 4-way decomposition  
319 method identified 15 proteins that significantly mediated the relationship between PA and  
320 incident dementia ( $p < 4.9 \times 10^{-5}$ ). Twelve proteins were found to mediate the relationship  
321 between MVPA and dementia; six proteins mediated the relationship between VPA and  
322 dementia, and five proteins mediated the relationship between SSOE and dementia (Table 2;  
323 Supplementary Tables S25). We did not identify any protein as a significant mediator of the  
324 effect of device-based measures on dementia.

325 Growth Differentiation Factor 15 (GDF15) mediated the effects of MVPA, VPA, and SSOE on  
326 dementia risk. Integrin Subunit Alpha V (ITGAV) demonstrated consistent mediating effects  
327 across MVPA, VPA, and SSOE. Integrin Subunit Alpha M (ITGAM) and Hematopoietic  
328 Prostaglandin D Synthase (HPGDS) mediated the effects of MVPA and SSOE on dementia risk.  
329 Glial Fibrillary Acidic Protein (GFAP) showed mediating effects of MVPA and VPA on  
330 dementia.

331

332

## 333 **DISCUSSION**

334

335 In this study, we aimed to explore how PA influences the plasma proteomic landscape and to  
336 identify proteins that mediate PA's protective effect on dementia. We conducted thorough  
337 analyses across 2,911 proteins to identify consistent findings across different PA measures and  
338 study designs. Conventional observational analyses revealed 1,027 proteins significantly  
339 associated with at least one of the six PA measures, and 41 proteins significantly associated with  
340 all six PA measures. We leveraged bi-directional MR analyses to validate and enhance the  
341 robustness of our findings regarding the putative causal effects of PA on protein levels. Pathway  
342 enrichment analyses revealed several biological pathways that may be upregulated in response to  
343 PA, and mediation analyses revealed specific proteins that may mediate the relationship between  
344 PA and dementia.

345

346 Our study extends previous findings by replicating several proteins such as FAP, LEP, CD209,  
347 CD248, MXRA8, WFIKKN2, ADM, APOA1, and IL6 (Robbins et al., 2023, Corlin et al.,

348 Stattin et al.).<sup>18,21,24,25</sup> We also identified many novel proteins and evaluated the evidence for  
349 causality and direction of effect between PA and each protein using a genetically-informed study  
350 design. The identified proteins fall into several broad functional categories, including  
351 cardiovascular and vascular regulation (e.g., ADM, ITGB5), lipid metabolism (e.g., APOA1,  
352 LPL), inflammatory and metabolic regulation (e.g., DPP4, GDF15, HPGDS), and tissue  
353 remodeling and fibrosis (e.g., FAP), highlighting the diverse physiological mechanisms through  
354 which PA influences critical cellular functions.<sup>47</sup>

355  
356 Across conventional observational, MR, mediation, and pathway enrichment analyses, we  
357 consistently identified the integrin family of proteins (e.g. ITGAV, ITGAM, and ITGA11) as  
358 increasing in response to PA, decreasing in response to SB, and mediating the effect of PA on  
359 all-cause dementia. Integrins are transmembrane receptors involved in cell adhesion and  
360 signaling and have been shown to significantly influence the extracellular matrix (ECM), critical  
361 for maintaining tissue integrity and facilitating cellular interactions.<sup>48</sup> Integrins such as ITGAV,  
362 ITGAM, and ITGA11 were consistently associated across multiple PA measures, underscoring  
363 the role of PA in ECM remodeling and cell-extracellular matrix adhesion. Another protein that  
364 we consistently identified was MXRA8, which is also involved in ECM processes.<sup>49</sup> MXRA8  
365 may interact with integrins such as ITGAV, playing a role in the maturation and maintenance of  
366 the blood-brain barrier.<sup>49</sup> Integrins could also explain the potential roles of PA in reducing the  
367 risk of all-cause dementia and Alzheimer's disease via facilitating cell-extracellular matrix  
368 adhesion functions that impact neuronal signaling pathways, synaptic plasticity,  
369 neuroinflammation, and blood-brain-barrier integrity.<sup>50</sup> Additionally, integrin-mediated  
370 pathways, such as those involving ITGA2 $\beta$ 1 and ITGAV $\beta$ 1, have been found to reduce amyloid-  
371 beta toxicity, further linking the positive effects of PA with brain health and reduced  
372 neurodegenerative risk.<sup>51</sup> Finally, integrins are strongly linked to irisin, a previously identified  
373 exerkin. <sup>52,53</sup> Irisin facilitates neurogenesis and amyloid-beta degradation through integrin  
374 receptors, such as ITGAV $\beta$ 5, on astrocytes and may also be involved with BDNF activation via  
375 integrin receptor complexes.<sup>52,53</sup>

376  
377 We also found that proteins such as IL-6, HPGDS, and GDF15 were consistently associated with  
378 PA and SB, implicating the modifications of inflammatory, metabolic, and vascular  
379 processes.<sup>54,55</sup> Previous studies have indicated that IL-6 and GDF15 levels may transiently rise  
380 following acute PA, but tend to decrease with sustained long-term PA, suggesting that our  
381 measurements may capture these lasting benefits effectively.<sup>56-60</sup> HPGDS was previously found  
382 to have a role in dementia via inflammatory pathways.<sup>55</sup> Notably, HPGDS and GDF15 also  
383 emerged as significant mediators between PA and the risk of all-cause dementia, suggesting that  
384 PA protects against dementia by reducing inflammation. The findings reinforce the broader  
385 evidence supporting the involvement of these proteins in neurodegenerative pathways.<sup>61</sup> The  
386 increase of HPGDS via PA could be related to prostaglandin-mediated inflammatory processes  
387 implicated in neurodegeneration, indicating the pathway of PA on dementia through HPGDS is

388 complex and may require further evaluation.<sup>55</sup> Elevated GDF15 has been previously associated  
389 with increased risks of all-cause dementia, vascular dementia, and Alzheimer's disease,  
390 particularly in the context of cerebrovascular damage.<sup>54,61,62</sup> The reduction in GDF15 that we  
391 observed with long-term PA suggests an anti-inflammatory compensatory response in the brain,  
392 which may minimize damage and promote recovery.<sup>61,62</sup> These results underscore the need to  
393 explore further associations between PA and these inflammatory markers and their role in  
394 vascular health, reducing neuroinflammation and promoting neuronal resilience.

395  
396 Other proteins that were consistently associated with PA included LPL, DPP4, FAP, LEP, and  
397 IGFBP1, which may play roles in cardiometabolic diseases and cancer. LPL, a protein that  
398 breaks down triglycerides into free fatty acids for energy, is increased with PA, which might help  
399 improve lipid profiles.<sup>63-65</sup> Another protein, FAP, which is primarily involved in tissue  
400 remodeling and fibrosis, was found to increase with PA. In previous research, elevated FAP  
401 expression after exercise correlated with improved cardiovascular metrics, such as VO<sub>2</sub> max,  
402 suggesting FAP's possible role in musculoskeletal tissue repair and cardiovascular health.<sup>66-69</sup>  
403 Moreover, we also identified LEP, a well-known metabolic hormone that regulates energy  
404 balance and satiety.<sup>70</sup> It consistently decreased with PA after controlling for percent body fat.  
405 This supports the previously reported role of PA in regulating appetite, possibly via LEP.<sup>71,72</sup>  
406 IGFBP1, which increases with PA, regulates insulin-like growth factors essential for glucose  
407 metabolism and cell growth.<sup>73</sup> Elevated IGFBP1 levels aid in better insulin regulation and  
408 metabolic stability, which may be crucial for preventing type-2 diabetes and supporting tissue  
409 repair.<sup>73,74</sup> Finally, we found that EGFR, another protein known for its role in cell growth and  
410 differentiation, increases with PA, which may help reduce cancer risk by preventing aberrant  
411 cellular proliferation.<sup>75</sup> Although PA has been studied as a protective factor for cancer, the  
412 relationship between PA and EGFR is not well understood, warranting further study.<sup>76</sup>

413  
414 Our study is notable because it is the largest and most comprehensive study of PA and plasma  
415 protein levels. Our approach included various self-reported and device-based PA measures,  
416 which allowed us to identify proteins with the most consistent associations across these  
417 measurement types, and proteins that exhibited associations with only a subset of measures.  
418 Employing a genetically-informed study design enabled us to examine the existence and  
419 direction of causal links between proteins and PA. Thus, specific proteins with consistent  
420 magnitudes and directions of association across study designs and PA measures could be  
421 identified. To assess the mediation of the PA-dementia relationship through specific proteins, we  
422 employed the 4-way decomposition method to disentangle the distinct contributions of PA's  
423 direct, indirect, and interactive effects on dementia through a given protein. This approach  
424 facilitated the identification of specific pathways and mechanisms that could underlie the  
425 protective effect of PA.

426

427 Analyses of device-based measures in our conventional observational design may be vulnerable  
428 to temporal ambiguity and potential reverse causation since there is a 4–8-year time gap between  
429 baseline blood sample collection and the device-based measure. However, our bidirectional MR  
430 analyses could provide some clarity as to any potential reverse causation. Mediation analyses  
431 might be prone to residual confounding and temporal ambiguity for the device-based measures,  
432 as mentioned above. Moreover, in mediation and interaction analyses, the total effect is only  
433 represented by exposure and mediator, making strong assumptions about unaccounted  
434 confounding and the independence of protein mediation. The study population primarily consists  
435 of middle-aged individuals of European descent, which limits the generalizability of the findings  
436 to other ancestries and age groups. Additionally, the MR approach relies on several assumptions,  
437 some of which are challenging to test. The gene-environment equivalence assumption posits that  
438 the downstream effects of genetic variants on a given exposure are like those of the  
439 environmental exposure itself, which may not always hold. Pleiotropy, as indicated in some  
440 cases by the colocalization analyses, is another assumption that may not hold. Finally, future  
441 population-level proteomics research must emphasize the need to consider and distinguish  
442 between secreted and leaked proteins when interpreting the proteomic changes in plasma in  
443 response to PA.

444  
445 We identified several proteins influenced by PA that span functions such as cell adhesion,  
446 inflammation, and cardiometabolic and neuroprotective roles. By integrating proteomic data with  
447 detailed epidemiological information and various study designs, our study provides novel  
448 insights into how PA affects health at the molecular level, potentially guiding precision public  
449 health interventions. These proteins reveal biological mechanisms that warrant closer  
450 investigation, especially in their role as molecular transducers of PA. The findings could inform  
451 strategies for tracking and enhancing PA behaviors and highlight biological pathways linked to  
452 dementia, which may be prioritized for therapeutic intervention.

453  
454 **SUPPLEMENTARY MATERIAL**  
455 Supplementary tables can be found in our GitHub repository: [https://github.com/klimentidis-](https://github.com/klimentidis-lab/ProteomicsofPhysicalActivity2024.git)  
456 [lab/ProteomicsofPhysicalActivity2024.git](https://github.com/klimentidis-lab/ProteomicsofPhysicalActivity2024.git)

457  
458 **DATA AND CODE AVAILABILITY**  
459  
460 Individual-level data from the UK Biobank can be requested at  
461 <https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>. Summary statistics for all  
462 GWAS used in this study are publicly available from the GWAS catalog <sup>(64)</sup> and UKB-PPP at  
463 <https://doi.org/10.7303/syn51364943>. Our analysis codes, and results including interactive  
464 visualizations of results, are available in a GitHub repository: [https://github.com/klimentidis-](https://github.com/klimentidis-lab/ProteomicsofPhysicalActivity2024.git)  
465 [lab/ProteomicsofPhysicalActivity2024.git](https://github.com/klimentidis-lab/ProteomicsofPhysicalActivity2024.git)

466

467

468 **ACKNOWLEDGMENTS**

469

470 This research has been conducted using the UK Biobank Resource under Application Number  
471 21259. It uses data provided by patients and collected by the NHS as part of their care and  
472 support. The authors thank the UK Biobank's organizers and participants.

473

474

475 **FUNDING**

476

477 The authors would also like to acknowledge funding from NIH R01AG072445.

478

479

480 **CONFLICT OF INTEREST**

481

482 The authors have no conflict of interest to report.

483

484

485

486

487

488

489

490 **REFERENCES**

- 491
- 492 1. King AC, Whitt-Glover MC, Marquez DX, et al. Physical Activity Promotion: Highlights  
493 from the 2018 Physical Activity Guidelines Advisory Committee Systematic Review. *Med Sci*  
494 *Sports Exerc.* 2019;51(6):1340-1353. doi:10.1249/MSS.0000000000001945
- 495 2. Hu MX, Turner D, Generaal E, et al. Exercise interventions for the prevention of depression: a  
496 systematic review of meta-analyses. *BMC Public Health.* 2020;20(1):1255.  
497 doi:10.1186/s12889-020-09323-y
- 498 3. Schuch FB, Stubbs B. The Role of Exercise in Preventing and Treating Depression. *Curr*  
499 *Sports Med Rep.* 2019;18(8):299-304. doi:10.1249/JSR.0000000000000620
- 500 4. Dougherty RJ, Jonaitis EM, Gaitán JM, et al. Cardiorespiratory fitness mitigates brain atrophy  
501 and cognitive decline in adults at risk for Alzheimer's disease. *Alzheimers Dement Diagn*  
502 *Assess Dis Monit.* 2021;13(1):e12212. doi:10.1002/dad2.12212
- 503 5. Barnes DE, Yaffe K, Satariano WA, Tager IB. A longitudinal study of cardiorespiratory  
504 fitness and cognitive function in healthy older adults. *J Am Geriatr Soc.* 2003;51(4):459-465.  
505 doi:10.1046/j.1532-5415.2003.51153.x
- 506 6. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic  
507 review of prospective evidence. *Psychol Med.* 2009;39(1):3-11.  
508 doi:10.1017/S0033291708003681
- 509 7. Raichlen DA, Aslan DH, Sayre MK, et al. Sedentary Behavior and Incident Dementia Among  
510 Older Adults. *JAMA.* 2023;330(10):934-940. doi:10.1001/jama.2023.15231
- 511 8. Vesperman CJ, Wang R, Schultz SA, et al. Cardiorespiratory fitness and cognition in persons  
512 at risk for Alzheimer's disease. *Alzheimers Dement Diagn Assess Dis Monit.*  
513 2022;14(1):e12330. doi:10.1002/dad2.12330
- 514 9. Rody T, De Amorim JA, De Felice FG. The emerging neuroprotective roles of exerkinines in  
515 Alzheimer's disease. *Front Aging Neurosci.* 2022;14. doi:10.3389/fnagi.2022.965190
- 516 10. Bray NW, Pieruccini-Faria F, Bartha R, Doherty TJ, Nagamatsu LS, Montero-Odasso M.  
517 The effect of physical exercise on functional brain network connectivity in older adults with  
518 and without cognitive impairment. A systematic review. *Mech Ageing Dev.* 2021;196:111493.  
519 doi:10.1016/j.mad.2021.111493
- 520 11. Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on  
521 brain and cognition. *Nat Rev Neurosci.* 2008;9(1):58-65. doi:10.1038/nrn2298
- 522 12. Dishman RK, Berthoud HR, Booth FW, et al. Neurobiology of Exercise. *Obesity.*  
523 2006;14(3):345-356. doi:10.1038/oby.2006.46
- 524 13. Intlekofer KA, Cotman CW. Exercise counteracts declining hippocampal function in  
525 aging and Alzheimer's disease. *Neurobiol Dis.* 2013;57:47-55. doi:10.1016/j.nbd.2012.06.011

- 526 14. Rabin JS, Klein H, Kirn DR, et al. Associations of Physical Activity and  $\beta$ -Amyloid With  
527 Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. *JAMA*  
528 *Neurol.* 2019;76(10):1203-1210. doi:10.1001/jamaneurol.2019.1879
- 529 15. Mandolesi L, Polverino A, Montuori S, et al. Effects of Physical Exercise on Cognitive  
530 Functioning and Wellbeing: Biological and Psychological Benefits. *Front Psychol.* 2018;9.  
531 doi:10.3389/fpsyg.2018.00509
- 532 16. Neuffer PD, Bamman MM, Muoio DM, et al. Understanding the Cellular and Molecular  
533 Mechanisms of Physical Activity-Induced Health Benefits. *Cell Metab.* 2015;22(1):4-11.  
534 doi:10.1016/j.cmet.2015.05.011
- 535 17. Smelik M, Zhao Y, Li X, et al. An interactive atlas of genomic, proteomic, and  
536 metabolomic biomarkers promotes the potential of proteins to predict complex diseases. *Sci*  
537 *Rep.* 2024;14(1):12710. doi:10.1038/s41598-024-63399-9
- 538 18. Stattin K, Lind L, Elmståhl S, et al. Physical activity is associated with a large number of  
539 cardiovascular-specific proteins: Cross-sectional analyses in two independent cohorts. *Eur J*  
540 *Prev Cardiol.* 2019;26(17):1865-1873. doi:10.1177/2047487319868033
- 541 19. Steffen BT, McDonough DJ, Pankow JS, et al. Plasma Neuronal Growth Regulator 1  
542 May Link Physical Activity to Reduced Risk of Type 2 Diabetes: A Proteome-Wide Study of  
543 ARIC Participants. *Diabetes.* 2024;73(2):318-324. doi:10.2337/db23-0383
- 544 20. Li H, Zhang Z, Qiu Y, et al. Proteome-wide mendelian randomization identifies causal  
545 plasma proteins in venous thromboembolism development. *J Hum Genet.* 2023;68(12):805-  
546 812. doi:10.1038/s10038-023-01186-6
- 547 21. Corlin L, Liu C, Lin H, et al. Proteomic Signatures of Lifestyle Risk Factors for  
548 Cardiovascular Disease: A Cross-Sectional Analysis of the Plasma Proteome in the  
549 Framingham Heart Study. *J Am Heart Assoc.* 2021;10(1):e018020.  
550 doi:10.1161/JAHA.120.018020
- 551 22. Kruger R. Proteomics insights on how physical inactivity can influence cardiovascular  
552 health. *Eur J Prev Cardiol.* 2019;26(17):1862-1864. doi:10.1177/2047487319872019
- 553 23. Lin X, Zhang X, Guo J, et al. Effects of Exercise Training on Cardiorespiratory Fitness  
554 and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of  
555 Randomized Controlled Trials. *J Am Heart Assoc.* 2015;4(7):e002014.  
556 doi:10.1161/JAHA.115.002014
- 557 24. Robbins JM, Peterson B, Schraner D, et al. Human plasma proteomic profiles indicative  
558 of cardiorespiratory fitness. *Nat Metab.* 2021;3(6):786-797. doi:10.1038/s42255-021-00400-z
- 559 25. Robbins JM, Rao P, Deng S, et al. Plasma proteomic changes in response to exercise  
560 training are associated with cardiorespiratory fitness adaptations. *JCI Insight.* 2023;8(7).  
561 doi:10.1172/jci.insight.165867

- 562 26. Hammerton G, Munafò MR. Causal inference with observational data: the need for  
563 triangulation of evidence. *Psychol Med.* 2021;51(4):563-578.  
564 doi:10.1017/S0033291720005127
- 565 27. Lawlor DA, Tilling K, Smith GD. Triangulation in aetiological epidemiology. *Int J*  
566 *Epidemiol.* 2016;45(6):1866. doi:10.1093/ije/dyw314
- 567 28. Lauer DJ, Russell AJ, Lynch HN, Thompson WJ, Mundt KA, Checkoway H.  
568 Triangulation of epidemiological evidence and risk of bias evaluation: A proposed framework  
569 and applied example using formaldehyde exposure and risk of myeloid leukemias. *Glob*  
570 *Epidemiol.* 2024;7:100143. doi:10.1016/j.gloepi.2024.100143
- 571 29. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for  
572 identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.*  
573 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 574 30. Sun J, Zhao J, Jiang F, et al. Identification of novel protein biomarkers and drug targets  
575 for colorectal cancer by integrating human plasma proteome with genome. *Genome Med.*  
576 2023;15(1):75. doi:10.1186/s13073-023-01229-9
- 577 31. R Core Team (2021). R: A language and environment for statistical computing. R  
578 Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- 579 32. Klimentidis YC, Raichlen DA, Bea J, et al. Genome-wide association study of habitual  
580 physical activity in over 377,000 UK Biobank participants identifies multiple variants  
581 including CADM2 and APOE. *Int J Obes* 2005. 2018;42(6):1161-1176. doi:10.1038/s41366-  
582 018-0120-3
- 583 33. Walmsley R, Chan S, Smith-Byrne K, et al. Reallocation of time between device-  
584 measured movement behaviours and risk of incident cardiovascular disease. *Br J Sports Med.*  
585 2022;56(18):1008-1017. doi:10.1136/bjsports-2021-104050
- 586 34. Chicco D, Agapito G. Nine quick tips for pathway enrichment analysis. *PLOS Comput*  
587 *Biol.* 2022;18(8):e1010348. doi:10.1371/journal.pcbi.1010348
- 588 35. Dennis G, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation,  
589 Visualization, and Integrated Discovery. *Genome Biol.* 2003;4(5):P3. doi:10.1186/gb-2003-4-  
590 5-p3
- 591 36. DAVID Functional Annotation Bioinformatics Microarray Analysis. Accessed July 2,  
592 2024. <https://david.ncifcrf.gov/>
- 593 37. Wang Z, Emmerich A, Pillon NJ, et al. Genome-wide association analyses of physical  
594 activity and sedentary behavior provide insights into underlying mechanisms and roles in  
595 disease prevention. *Nat Genet.* 2022;54(9):1332-1344. doi:10.1038/s41588-022-01165-1



- 596 38. Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and  
597 health in the UK Biobank. *Nature*. 2023;622(7982):329-338. doi:10.1038/s41586-023-06592-  
598 6
- 599 39. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal  
600 inference in epidemiological studies. *Hum Mol Genet*. 2014;23(R1):R89-98.  
601 doi:10.1093/hmg/ddu328
- 602 40. Two Sample MR Functions and Interface to MR Base Database. Accessed July 2, 2024.  
603 <https://mrcieu.github.io/TwoSampleMR/>
- 604 41. Ramadan FA, Bea JW, Garcia DO, et al. Association of sedentary and physical activity  
605 behaviours with body composition: a genome-wide association and Mendelian randomisation  
606 study. *BMJ Open Sport Exerc Med*. Published online August 2, 2022. doi:10.1136/bmjsem-  
607 2021-001291
- 608 42. Wang Z, Davey Smith G, Loos RJF, den Hoed M. Distilling causality between physical  
609 activity traits and obesity via Mendelian randomization. *Commun Med*. 2023;3(1):1-6.  
610 doi:10.1038/s43856-023-00407-5
- 611 43. Colocalisation Tests of Two Genetic Traits. Accessed July 2, 2024.  
612 <https://chr1swallace.github.io/coloc/>
- 613 44. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation  
614 between pairs of genetic association studies using summary statistics. *PLoS Genet*.  
615 2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383
- 616 45. VanderWeele TJ. A unification of mediation and interaction: a 4-way decomposition.  
617 *Epidemiol Camb Mass*. 2014;25(5):749-761. doi:10.1097/EDE.0000000000000121
- 618 46. Discacciati A, Bellavia A, Lee JJ, Mazumdar M, Valeri L. Med4way: a Stata command  
619 to investigate mediating and interactive mechanisms using the four-way effect decomposition.  
620 *Int J Epidemiol*. Published online November 16, 2018. doi:10.1093/ije/dyy236
- 621 47. UniProt. Accessed December 15, 2024. <https://www.uniprot.org/>
- 622 48. Danen EHJ. Integrins: An Overview of Structural and Functional Aspects. In: *Madame*  
623 *Curie Bioscience Database [Internet]*. Landes Bioscience; 2013. Accessed July 2, 2024.  
624 <https://www.ncbi.nlm.nih.gov/books/NBK6259/>
- 625 49. Han SW, Jung YK, Lee EJ, et al. DICAM inhibits angiogenesis via suppression of AKT  
626 and p38 MAP kinase signalling. *Cardiovasc Res*. 2013;98(1):73-82. doi:10.1093/cvr/cvt019
- 627 50. Biose IJ, Ismael S, Ouvrier B, White AL, Bix GJ. The Potential Role of Integrin  
628 Signaling in Memory and Cognitive Impairment. *Biomolecules*. 2023;13(1):108.  
629 doi:10.3390/biom13010108

- 630 51. Ortiz-Sanz C, Llaveró F, Zuazo-Ibarra J, et al. Recombinant Integrin  $\beta$ 1 Signal Peptide  
631 Blocks Gliosis Induced by A $\beta$  Oligomers. *Int J Mol Sci.* 2022;23(10):5747.  
632 doi:10.3390/ijms23105747
- 633 52. Kim H, Wrann CD, Jedrychowski M, et al. Irisin Mediates Effects on Bone and Fat via  
634  $\alpha$ V Integrin Receptors. *Cell.* 2018;175(7):1756-1768.e17. doi:10.1016/j.cell.2018.10.025
- 635 53. A M, Wales TE, Zhou H, et al. Irisin acts through its integrin receptor in a two-step  
636 process involving extracellular Hsp90 $\alpha$ . *Mol Cell.* 2023;83(11):1903-1920.e12.  
637 doi:10.1016/j.molcel.2023.05.008
- 638 54. Wischhusen J, Melero I, Fridman WH. Growth/Differentiation Factor-15 (GDF-15):  
639 From Biomarker to Novel Targetable Immune Checkpoint. *Front Immunol.* 2020;11:951.  
640 doi:10.3389/fimmu.2020.00951
- 641 55. Mohri I, Kadoyama K, Kanekiyo T, et al. Hematopoietic prostaglandin D synthase and  
642 DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques  
643 from human patients and in a mouse model of Alzheimer disease. *J Neuropathol Exp Neurol.*  
644 2007;66(6):469-480. doi:10.1097/01.jnen.0000240472.43038.27
- 645 56. Quist JS, Klein AB, Færch K, et al. Effects of acute exercise and exercise training on  
646 plasma GDF15 concentrations and associations with appetite and cardiometabolic health in  
647 individuals with overweight or obesity – A secondary analysis of a randomized controlled  
648 trial. *Appetite.* 2023;182:106423. doi:10.1016/j.appet.2022.106423
- 649 57. Kleinert M, Clemmensen C, Sjøberg KA, et al. Exercise increases circulating GDF15 in  
650 humans. *Mol Metab.* 2018;9:187-191. doi:10.1016/j.molmet.2017.12.016
- 651 58. Klein AB, Kleinert M, Richter EA, Clemmensen C. GDF15 in Appetite and Exercise:  
652 Essential Player or Coincidental Bystander? *Endocrinology.* 2022;163(1):bqab242.  
653 doi:10.1210/endocr/bqab242
- 654 59. Nash D, Hughes MG, Butcher L, et al. IL-6 signaling in acute exercise and chronic  
655 training: Potential consequences for health and athletic performance. *Scand J Med Sci Sports.*  
656 2023;33(1):4-19. doi:10.1111/sms.14241
- 657 60. Shobeiri P, Seyedmirzaei H, Karimi N, et al. IL-6 and TNF- $\alpha$  responses to acute and  
658 regular exercise in adult individuals with multiple sclerosis (MS): a systematic review and  
659 meta-analysis. *Eur J Med Res.* 2022;27(1):185. doi:10.1186/s40001-022-00814-9
- 660 61. Walker KA, Chen J, Zhang J, et al. Large-scale plasma proteomic analysis identifies  
661 proteins and pathways associated with dementia risk. *Nat Aging.* 2021;1(5):473-489.  
662 doi:10.1038/s43587-021-00064-0
- 663 62. Guo Y, You J, Zhang Y, et al. Plasma proteomic profiles predict future dementia in  
664 healthy adults. *Nat Aging.* 2024;4(2):247-260. doi:10.1038/s43587-023-00565-0

- 665 63. Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. *Lipids Health Dis.*  
666 2017;16(1):132. doi:10.1186/s12944-017-0515-5
- 667 64. Harrison M, Moyna NM, Zderic TW, et al. Lipoprotein particle distribution and skeletal  
668 muscle lipoprotein lipase activity after acute exercise. *Lipids Health Dis.* 2012;11(1):64.  
669 doi:10.1186/1476-511X-11-64
- 670 65. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH, Stacpoole PW. Exercise  
671 Training, Without Weight Loss, Increases Insulin Sensitivity and Postheparin Plasma Lipase  
672 Activity in Previously Sedentary Adults. *Diabetes Care.* 2003;26(3):557-562.  
673 doi:10.2337/diacare.26.3.557
- 674 66. Cui Y, Wang Y, Wang S, Du B, Li X, Li Y. Highlighting Fibroblasts Activation in  
675 Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in  
676 Cardiovascular Diseases. *J Clin Med.* 2023;12(18):6033. doi:10.3390/jcm12186033
- 677 67. Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by  
678 inflammation and degrades type I collagen in thin-cap fibroatheromata. *Eur Heart J.*  
679 2011;32(21):2713-2722. doi:10.1093/eurheartj/ehq519
- 680 68. Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and  
681 malignancy. *Cancer Metastasis Rev.* 2020;39(3):783-803. doi:10.1007/s10555-020-09909-3
- 682 69. Zhang Z, Tao J, Qiu J, et al. From basic research to clinical application: targeting  
683 fibroblast activation protein for cancer diagnosis and treatment. *Cell Oncol.* 2024;47(2):361-  
684 381. doi:10.1007/s13402-023-00872-z
- 685 70. Vilariño-García T, Polonio-González ML, Pérez-Pérez A, et al. Role of Leptin in  
686 Obesity, Cardiovascular Disease, and Type 2 Diabetes. *Int J Mol Sci.* 2024;25(4):2338.  
687 doi:10.3390/ijms25042338
- 688 71. Jadhav RA, Maiya GA, Hombali A, Umakanth S, Shivashankar KN. Effect of physical  
689 activity promotion on adiponectin, leptin and other inflammatory markers in prediabetes: a  
690 systematic review and meta-analysis of randomized controlled trials. *Acta Diabetol.*  
691 2021;58(4):419-429. doi:10.1007/s00592-020-01626-1
- 692 72. Anche P, Maiya GA, Kamath SU, Shastry BA. Influence of a 12-week physical activity  
693 program on leptin resistance in metabolic syndrome: a preliminary study. *Int J Diabetes Dev*  
694 *CTries.* 2021;41(4):600-606. doi:10.1007/s13410-021-00928-6
- 695 73. Rajwani A, Ezzat V, Smith J, et al. Increasing Circulating IGFBP1 Levels Improves  
696 Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects  
697 Against Atherosclerosis. *Diabetes.* 2012;61(4):915-924. doi:10.2337/db11-0963
- 698 74. Aziz A, Haywood NJ, Cordell PA, et al. Insulinlike Growth Factor–Binding Protein-1  
699 Improves Vascular Endothelial Repair in Male Mice in the Setting of Insulin Resistance.  
700 *Endocrinology.* 2018;159(2):696-709. doi:10.1210/en.2017-00572

701 75. Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function  
702 on Board. *Front Oncol.* 2019;9. doi:10.3389/fonc.2019.00800


703 76. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical Activity in Cancer  
704 Prevention and Survival: A Systematic Review. *Med Sci Sports Exerc.* 2019;51(6):1252.  
705 doi:10.1249/MSS.0000000000001937

706

707

708 FIGURES AND TABLES

709




710

711 **Figure 1:** Study design and analytical framework for investigating the relationship of physical  
712 activity and sedentary behaviors with plasma proteins and incident all-cause dementia.

713 The framework consists of four main components: (1) Phenotypic (conventional observational) associations:  
714 Analysis of associations between PA measures and 2,911 plasma proteins from the UK Biobank, with sample  
715 sizes ranging from  $n = 9,496$  to  $n = 39,160$ . (2) Pathway enrichment analyses: Identification of protein  
716 signaling pathways, Gene Ontology (GO) biological processes, and GO molecular functions enriched among  
717 the associated proteins. (3) Bi-directional Mendelian randomization: Examination of causal relationships  
718 between PA and proteins using genetic instruments (SNPs) for both PA and protein levels, employing  
719 Mendelian Randomization (MR) methods such as Inverse Variance Weighted (IVW), Wald Ratio, and MR-  
720 Egger. (4) Mediation and interaction analyses: Assessment of the direct, indirect, mediated interaction, and  
721 interaction effects of PA-associated proteins on the risk of clinically diagnosed incident all-cause dementia.  
722 .(Created with [BioRender.com](https://BioRender.com))

723

724




725  
 726 **Figure 2:** Volcano plots showing the associations of physical activity (PA) and sedentary  
 727 behavior (SB) measures with protein levels. The six panels illustrate different PA measures, including self-  
 728 reported measures (Moderate to Vigorous Physical Activity [MVPA], Vigorous Physical Activity [VPA], Strenuous  
 729 Sport or Other Exercise [SSOE]) on the top row, and device-wear measures (Average Acceleration, Fraction  
 730 Acceleration milligravities, Sedentary Behavior) on the bottom row. The y-axis in all panels represents the  $-\log_{10}(p)$   
 731 of the associations. For continuous PA measures, the x-axis shows the  $\beta$  coefficient per 1 standard deviation (SD)  
 732 increase in PA. In contrast, for binary measures (VPA and SSOE), it represents the  $\beta$  coefficient per unit increase.  
 733 Each point corresponds to a protein, with significant positive associations ( $p < 1.7 \times 10^{-5}$ , denoted by the gray  
 734 horizontal dashed line) highlighted in purple (self-reported measures) and blue (device-wear measures). Significant  
 735 negative associations are depicted in orange (self-reported measures) and red (device-wear measures).  
 736

737 **Table 1:** Enrichment of Gene Ontology biological process and molecular function terms (with  
 738 Benjamini FDR <0.05) among the genes coding for the set of 41 proteins that were associated  
 739 with all PA measures.

Enriched term	Gene (n)	Benjamini FDR q-value	Gene Names
Integrin binding	12	8.8E-07	ADAMTS8,GFRA1,COMP,EGFR,FAP,ITGA11,ITGA2,ITGAM,ITGAV,ITGB1,ITGB2,ITGB5
Cell adhesion mediated by integrin	7	3.3E-05	ITGA11,ITGA2,ITGAM,ITGAV,ITGB1,ITGB2,ITGB5
Cell-matrix adhesion	9	5.1E-05	CD34,L1CAM,ITGA11,ITGA2,ITGAM,ITGAV,ITGB1,ITGB2,ITGB5
Virus receptor activity	8	2.5E-04	CLEC4M,CD209,DPP4,EGFR,ITGA2,ITGAV,ITGB1,ITGB5
Integrin-mediated signaling pathway	8	5.7E-04	APOA1,ITGA11,ITGA2,ITGAM,ITGAV,ITGB1,ITGB2,ITGB5
Symbiont entry into host cell	8	1.8E-03	CLEC4M,CD209,DPP4,EGFR,ITGA2,ITGAV,ITGB1,ITGB5
Cell-cell adhesion	9	5.1E-03	CD34,EGFR,ITGA11,ITGA2,ITGAM,ITGAV,ITGB1,ITGB2,ITGB5
Cell adhesion	12	1.2E-02	CLEC4A,L1CAM,COMP,DPP4,FAP,ITGA11,ITGA2,ITGAM,ITGAV,ITGB1,ITGB2,MXRA8
Collagen binding involved in cell-matrix adhesion	3	2.5E-02	ITGA11,ITGA2,ITGB1
D-mannose binding	4	2.7E-02	CLEC10A,CLEC4A,CLEC4M,CD209
Negative regulation of vasoconstriction	3	4.7E-02	ADM,ITGB1,LEP

740 **Benjamini FDR q-value-** This represents the false discovery rate (FDR) adjusted p according to the Benjamini-  
 741 Hochberg procedure, presenting here significant results after correcting for the multiple testing. This ensures that the  
 742 reported enriched terms are statistically significant with an acceptable rate of false positives. **Enriched term-** The  
 743 enriched Gene Ontology (GO) biological processes and molecular function terms that were identified as  
 744 overrepresented among the genes coding for the proteins significantly associated with physical activity measures.  
 745

746




747

748

749 **Figure 3:** Volcano plots depicting Mendelian randomization results of genetically-predicted  
 750 physical activity (PA) and sedentary behavior (SB) measures on protein levels, using IVW or  
 751 Wald ratio methods. The top row shows results using exposure SNPs with p-values below the stringent genome-  
 752 wide significance threshold ( $p < 5 \times 10^{-8}$ ), while the bottom row displays results using exposure SNPs with  
 753 associations at a more liberal genome-wide threshold ( $p < 5 \times 10^{-6}$ ). Both rows highlight each PA and SB measure  
 754 related to protein levels adjusted for an additional significance threshold of  $p < 4.9 \times 10^{-5}$ , indicated by the  
 755 horizontal gray dashed line. Proteins with significant positive associations are highlighted in purple for self-reported  
 756 measures and blue for device-wear measures, while proteins with significant negative associations are shown in  
 757 orange and red.  
 758



759



760

761

**Figure 4.** Comparison of observational and Mendelian Randomization effect estimates for the

762 associations between physical activity exposures and protein levels. The figures demonstrate the  
 763 relationship between beta coefficients derived from conventional observational associations (y-axis) and MR  
 764 analyses (x-axis) for self-reported PA measures (Moderate to Vigorous Physical Activity, Vigorous Physical  
 765 Activity, Strenuous Sports or Other Exercises) and device-wear measures (Acceleration Average, Fraction  
 766 Acceleration > 425 milligravities). Each colored data point corresponds to a protein, with significant associations in  
 767 both the observational and MR analyses ( $p < 1 \times 10^{-3}$ ) highlighted. These plots offer a visual comparison to evaluate  
 768 the consistency in effect estimates across both observational and MR analyses, which may imply causal  
 769 relationships. (Created in part with [BioRender.com](https://www.bio-render.com/))

770

771

772 **Table 2.** Mediation analysis results show the proteins that significantly mediated the relationship  
 773 between PA and all-cause dementia.

PA measure	Protein	Pure indirect effect	P <sup>1</sup>
<b>MVPA</b>	GDF15; Growth/differentiation factor 15	-0.01 [-0.02, 0.01]	1.69E-07
	HPGDS; Hematopoietic prostaglandin D synthase	-0.01 [-0.02, -0.01]	4.81E-07
	ITGAV; Integrin alpha V	-0.02 [-0.02, -0.01]	8.38E-07
	MENT; Protein MENT	0.01 [-0.02, -0.01]	3.06E-06
	ITGAM; Integrin alpha M	-0.01 [-0.02, -0.01]	7.31E-06
<b>VPA</b>	ITGAV; Integrin alpha V	-0.06 [-0.08, -0.03]	2.62E-06
	HPGDS; Hematopoietic prostaglandin D synthase	-0.04 [-0.06, -0.02]	3.28E-06
	GDF15; Growth/differentiation factor 15	-0.04 [-0.06, -0.02]	1.18E-05
<b>SSOE</b>	GDF15; Growth/differentiation factor 15	-0.05 [-0.06, -0.03]	8.38E-08
	HPGDS; Hematopoietic prostaglandin D synthase	-0.03 [-0.04, -0.03]	6.52E-07
	ITGAV; Integrin alpha V	-0.03 [-0.05, -0.02]	1.13E-05
	ITGAM; Integrin alpha M	-0.02 [-0.03, -0.01]	3.27E-05
	BCAN; Brevican core protein	-0.02 [-0.03, -0.01]	3.38E-05

774  
 775 **Pure indirect effect (PIE):** This represents the estimated indirect effect of the protein on the relationship between  
 776 physical activity and dementia based on the 4-way decomposition, with 95% confidence intervals provided in  
 777 parentheses. **P:** The p-value for the pure indirect effect. Lower values indicate stronger evidence against the null  
 778 hypothesis (that there is no mediation effect).<sup>1</sup> Presented here are the protein mediators that are statistically  
 779 significant after correction for multiple testing ( $p < 4.9 \times 10^{-5}$ )